Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Longitudinal evaluation of neuroinflammation and oxidative stress in a mouse model of Alzheimer disease using positron emission tomography.

Tytuł:
Longitudinal evaluation of neuroinflammation and oxidative stress in a mouse model of Alzheimer disease using positron emission tomography.
Autorzy:
Rejc L; CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Paseo Miramon 182, 20014, San Sebastian, Spain. .
Gómez-Vallejo V; CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Paseo Miramon 182, 20014, San Sebastian, Spain.
Joya A; CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Paseo Miramon 182, 20014, San Sebastian, Spain.; Laboratory of Neuroimaging and biomarkers of inflammation, UPV/EHU, Sede building B. Sarriena, Achucarro Basque Center for Neuroscience, 48940, Science ParkLeioa, Spain.
Arsequell G; Institut de Química Avançada de Catalunya (IQAC), Spanish National Research Council (IQAC-CSIC), 08034, Barcelona, Spain.
Egimendia A; CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Paseo Miramon 182, 20014, San Sebastian, Spain.
Castellnou P; CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Paseo Miramon 182, 20014, San Sebastian, Spain.
Ríos-Anglada X; CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Paseo Miramon 182, 20014, San Sebastian, Spain.
Cossío U; CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Paseo Miramon 182, 20014, San Sebastian, Spain.
Baz Z; CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Paseo Miramon 182, 20014, San Sebastian, Spain.
Iglesias L; Laboratory of Neuroimaging and biomarkers of inflammation, UPV/EHU, Sede building B. Sarriena, Achucarro Basque Center for Neuroscience, 48940, Science ParkLeioa, Spain.
Capetillo-Zarate E; Faculty of Medicine and Nursery, University of the Basque Country UPV/EHU, Achucarro Basque Center for Neuroscience and CIBERNED, Barrio Sarriena S/N, 48940, Leioa, Spain.; Basque Foundation for Science, IKERBASQUE, 48009, Bilbao, Spain.
Ramos-Cabrer P; CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Paseo Miramon 182, 20014, San Sebastian, Spain.; Basque Foundation for Science, IKERBASQUE, 48009, Bilbao, Spain.
Martin A; Laboratory of Neuroimaging and biomarkers of inflammation, UPV/EHU, Sede building B. Sarriena, Achucarro Basque Center for Neuroscience, 48940, Science ParkLeioa, Spain.; Basque Foundation for Science, IKERBASQUE, 48009, Bilbao, Spain.
Llop J; CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Paseo Miramon 182, 20014, San Sebastian, Spain. .
Źródło:
Alzheimer's research & therapy [Alzheimers Res Ther] 2022 Jun 09; Vol. 14 (1), pp. 80. Date of Electronic Publication: 2022 Jun 09.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: [London] : BioMed Central Ltd.
MeSH Terms:
Alzheimer Disease*/pathology
Amyloidosis*
Animals ; Disease Models, Animal ; Disease Progression ; Humans ; Mice ; Neuroinflammatory Diseases ; Oxidative Stress ; Positron-Emission Tomography/methods ; Receptors, GABA/metabolism
References:
Front Physiol. 2020 Sep 23;11:973. (PMID: 33071801)
EMBO Mol Med. 2016 Jun 01;8(6):595-608. (PMID: 27025652)
Lancet Neurol. 2020 Nov;19(11):940-950. (PMID: 33098803)
JAMA Intern Med. 2021 Oct 1;181(10):1276-1278. (PMID: 34254984)
Redox Biol. 2018 Apr;14:450-464. (PMID: 29080524)
Neuron. 1992 Jan;8(1):159-68. (PMID: 1530909)
Biochim Biophys Acta. 2000 Jul 26;1502(1):139-44. (PMID: 10899439)
J Cereb Blood Flow Metab. 2010 Jan;30(1):230-41. (PMID: 19794397)
EJNMMI Res. 2017 Nov 25;7(1):93. (PMID: 29177913)
Cell Mol Neurobiol. 2016 Mar;36(2):155-65. (PMID: 26328781)
Nat Rev Neurol. 2019 Jul;15(7):365-366. (PMID: 31138932)
J Neuroinflammation. 2018 Feb 22;15(1):55. (PMID: 29471880)
Neuropharmacology. 2004 Feb;46(2):273-84. (PMID: 14680765)
Theranostics. 2021 Apr 26;11(13):6542-6559. (PMID: 33995675)
Pharmacol Rev. 2012 Jul;64(3):780-802. (PMID: 22759795)
Alzheimers Dement. 2018 Apr;14(4):535-562. (PMID: 29653606)
J Cereb Blood Flow Metab. 2017 Aug;37(8):2870-2882. (PMID: 27834284)
Front Aging Neurosci. 2021 Jul 23;13:713726. (PMID: 34366832)
Neurobiol Aging. 2000 May-Jun;21(3):383-421. (PMID: 10858586)
Lancet Neurol. 2019 Jan;18(1):88-106. (PMID: 30497964)
Mol Imaging. 2018 Jan-Dec;17:1536012118792317. (PMID: 30203712)
EJNMMI Res. 2020 Aug 28;10(1):100. (PMID: 32857284)
Eur J Nucl Med Mol Imaging. 2021 Dec;49(1):77-109. (PMID: 34245328)
Trends Neurosci. 2017 Jun;40(6):347-357. (PMID: 28494972)
Clin Cancer Res. 2011 Sep 15;17(18):6000-11. (PMID: 21750203)
Mol Imaging Biol. 2014 Apr;16(2):264-73. (PMID: 24002615)
J Neurosci. 2006 Oct 4;26(40):10129-40. (PMID: 17021169)
Glia. 2016 Jun;64(6):993-1006. (PMID: 26959396)
Theranostics. 2016 Jul 09;6(11):1753-67. (PMID: 27570548)
J Neurochem. 2019 May;149(4):438-451. (PMID: 30339715)
Oxid Med Cell Longev. 2017;2017:1809592. (PMID: 28194255)
Drugs Context. 2021 Oct 04;10:. (PMID: 34650610)
Contributed Indexing:
Keywords: Alzheimer disease; Oxidative stress; Positron emission tomography; TSPO
Substance Nomenclature:
0 (Receptors, GABA)
0 (TSPO protein, human)
Entry Date(s):
Date Created: 20220608 Date Completed: 20220610 Latest Revision: 20220804
Update Code:
20240105
PubMed Central ID:
PMC9178858
DOI:
10.1186/s13195-022-01016-5
PMID:
35676734
Czasopismo naukowe
Background: Validation of new biomarkers of Alzheimer disease (AD) is crucial for the successful development and implementation of treatment strategies. Additional to traditional AT(N) biomarkers, neuroinflammation biomarkers, such as translocator protein (TSPO) and cystine/glutamine antiporter system (x c - ), could be considered when assessing AD progression. Herein, we report the longitudinal investigation of [ 18 F]DPA-714 and [ 18 F]FSPG for their ability to detect TSPO and x c - biomarkers, respectively, in the 5xFAD mouse model for AD.
Methods: Expression of TSPO and x c - system was assessed longitudinally (2-12 months of age) on 5xFAD mice and their respective controls by positron emission tomography (PET) imaging using radioligands [ 18 F]DPA-714 and [ 18 F]FSPG. In parallel, in the same mice, amyloid-β plaque deposition was assessed with the amyloid PET radiotracer [ 18 F]florbetaben. In vivo findings were correlated to ex vivo immunofluorescence staining of TSPO and x c - in microglia/macrophages and astrocytes on brain slices. Physiological changes of the brain tissue were assessed by magnetic resonance imaging (MRI) in 12-month-old mice.
Results: PET studies showed a significant increase in the uptake of [ 18 F]DPA-714 and [ 18 F]FSPG in the cortex, hippocampus, and thalamus in 5xFAD but not in WT mice over time. The results correlate with Aβ plaque deposition. Ex vivo staining confirmed higher TSPO overexpression in both, microglia/macrophages and astrocytes, and overexpression of x c - in non-glial cells of 5xFAD mice. Additionally, the results show that Aβ plaques were surrounded by microglia/macrophages overexpressing TSPO. MRI studies showed significant tissue shrinkage and microstructural alterations in 5xFAD mice compared to controls.
Conclusions: TSPO and x c - overexpression can be assessed by [ 18 F]DPA-714 and [ 18 F]FSPG, respectively, and correlate with the level of Aβ plaque deposition obtained with a PET amyloid tracer. These results position the two tracers as promising imaging tools for the evaluation of disease progression. Longitudinal in vivo study in the 5xFAD mouse model shows that TSPO and oxidative stress assessment through [ 18 F]DPA-714 and [ 18 F]FSPG-PET imaging, respectively, could serve as a potential tool for the evaluation of Alzheimer disease progression.
(© 2022. The Author(s).)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies